Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917994 | PMC |
| http://dx.doi.org/10.1002/ajh.25560 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Venetoclax is a novel drug that improves outcomes for chronic lymphocytic leukemia (CLL) patients, showing that early treatment response can predict long-term success.
- Researchers used mass cytometry to analyze blood samples from CLL patients and found that venetoclax significantly reduced various CLL cell subpopulations while increasing survival proteins in the remaining cells.
- The study suggests that CLL cells quickly adapt to therapies through survival signals like the B-cell activating factor (BAFF), indicating that combining treatments might lead to more effective and lasting results.
Comparing the Efficacy and Safety of First-Line Treatments for Chronic Lymphocytic Leukemia: A Network Meta-Analysis.
J Natl Cancer Inst
October 2024
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Article Synopsis
- The treatment approach for Chronic Lymphocytic Leukemia (CLL) is shifting from chemotherapy to chemo-free regimens, and this study utilizes frequentist network meta-analysis to compare various treatment options effectively.
- The analysis included 30 trials with 12,818 patients, focusing on first-line treatments and measuring outcomes like progression-free survival (PFS), minimal residual disease, and adverse events across different patient groups.
- Acalabrutinib showed generally better PFS in older patients and those with certain comorbidities, while other treatments had varying benefits and side effects, highlighting the importance of personalized treatment strategies based on individual patient characteristics.
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
October 2024
Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy.
Article Synopsis
- The study investigates a chemotherapy-free treatment combining atezolizumab, venetoclax, and obinutuzumab for patients with diffuse large B-cell lymphoma variant of Richter transformation, which is known for being difficult to treat and having a poor prognosis.
- It was a phase 2, multicenter trial involving 15 hospitals across Italy and Switzerland, targeting patients with a specific type of cancer transformation after certain prior conditions.
- The primary goal was to achieve an overall response rate of at least 67% by day 21 of cycle 6, with the study being registered under ClinicalTrials.gov, NCT04082897, and completed by October 2022.*
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Blood
October 2024
Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.
In the CLL14 study, patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions were randomized to 12 cycles of venetoclax-obinutuzumab (Ven-Obi, n = 216) or chlorambucil-obinutuzumab (Clb-Obi, n = 216). Progression-free survival (PFS) was the primary end point. Key secondary end points included time-to-next-treatment (TTNT), rates of undetectable minimal residual disease (uMRD), overall survival (OS), and rates of adverse events.
View Article and Find Full Text PDFAssay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis.
Sci Rep
July 2024
Cancer Control Research, BC Cancer, Vancouver, Canada.
Costly targeted cancer treatments challenge publicly-funded healthcare systems seeking to align expected benefit with value for money. In 2021, The Canadian Agency for Drugs and Technologies in Health (CADTH) published a provisional funding algorithm for risk-based treatment of chronic lymphocytic leukemia (CLL). We estimate the cost-effectiveness of this algorithm against current standard of care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!